Jubilant Ingrevia Q1 FY27 Revenue Up 25% to ₹1,300 Cr, EBITDA Rises 36%
Jubilant Ingrevia reported Q1 FY27 results with revenue up 25% YoY to ₹1,300 Cr and EBITDA up 36% YoY to ₹209 Cr. PAT grew 41% YoY to ₹106 Cr. Specialty Chemicals revenue increased 11% YoY, Nutrition grew 36% YoY, and Chemical Intermediates revenue surged 38% YoY.
The significant year-on-year growth in key financial metrics and positive management outlook suggests a material positive impact on investor sentiment and the company's valuation.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with positive commentary on market conditions and future outlook.
Jubilant Ingrevia Limited announced its financial results for the first quarter ended June 30, 2026, reporting a strong start to FY27. The company's total revenue grew by 25% year-on-year (YoY) to ₹1,300 crore, while EBITDA increased by 36% YoY to ₹209 crore. Profit After Tax (PAT) saw a significant jump of 41% YoY to ₹106 crore, with Basic and Diluted EPS at ₹6.7.
The company highlighted resilient demand across the chemical industry, with stable volumes and firming prices. The Pharmaceuticals segment continued to be a key growth driver, supported by strong volume growth. Agrochemicals showed signs of recovery, and the Nutrition and Personal Care market witnessed healthy growth, particularly in Niacinamide and Choline realizations.
Management expressed confidence in the 'Pinnacle journey', expecting continued growth momentum led by Specialty Chemicals and Nutrition, alongside a recovery in Acetyls. The new Multi-Purpose Plant is on track for commissioning by the end of the calendar year.
In the Specialty Chemicals segment, revenue grew 11% YoY to ₹533 crore, with EBITDA at ₹139 crore. The Nutrition segment reported a 36% YoY revenue growth to ₹243 crore and the highest EBITDA in three years at ₹36 crore. Chemical Intermediates business saw a strong rebound with revenue up 38% YoY to ₹524 crore and EBITDA surging 240% YoY to ₹57 crore.
The company also hosted an Investor & Analyst Day on June 30, 2026, at its Bharuch facility, reinforcing confidence in its manufacturing capabilities and growth prospects.
What to do with a filing like this
Jubilant Ingrevia Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Ingrevia Limited. Read the original for the full detail.